Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Carmustine

Drug class: Alkylating Drug

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Carmustine used for?
The FDA-approved label (Gliadel, Azurity Pharmaceuticals, Inc., December 5, 2024) says: “GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation and recurrent glioblastoma as an adjunct to surgery” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Carmustine have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Carmustine?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Carmustine been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Carmustine?
1 company lists prescription products of Carmustine in the FDA NDC Directory, including Azurity Pharmaceuticals, Inc..

What Carmustine is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation and recurrent glioblastoma as an adjunct to surgery

— FDA label: Gliadel, Azurity Pharmaceuticals, Inc., effective December 5, 2024. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Forms and how it is given

Dosage formsWafer
RouteIntracavitary
Prescription products1 in the FDA NDC Directory
Brand namesGliadel

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA020637
GLIADEL
AzuritySeptember 23, 1996 21, latest December 5, 2018
2018: Labeling · 2015: Manufacturing (CMC) · 2014: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)212994, 309013
SPL set ID of the quoted label38962a55-a514-4c48-bea5-f99a8da4beec
FDA labels (SPL)1
FDA applicationsNDA020637
Active ingredients (FDA)CARMUSTINE

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Gliadel, Azurity Pharmaceuticals, Inc., effective December 5, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers